Submission date
04/06/2007
Registration date
23/07/2007
Last edited
07/05/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
? Protocol not yet added
? SAP not yet added
Results added
? Raw data not yet added
Study completed

Contact information

Type

Scientific

Contact name

Prof Peter J Hoskin

ORCID ID

Contact details

Marie Curie Research Wing
Mount Vernon Hospital
Rickmansworth Road
Northwood
Middlesex
Northwood
HA6 2RN
United Kingdom
+44 (0)1923 844533
peterhoskin@nhs.net

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00727584

Protocol/serial number

BRD/07/010

Study information

Scientific title

A randomised feasibility study of single fraction radiotherapy compared to multi-fraction radiotherapy in patients with metastatic spinal cord compression

Acronym

SCORAD feasibility study

Study hypothesis

To examine whether a phase III randomised trial comparing a single fraction of radiotherapy with multi-fraction radiotherapy is acceptable to clinicians and patients.

Ethics approval(s)

Cornwall and Plymouth Research Ethics Committee approved before patient recruitment began, ref: 07/H0203/167

Study design

Randomized controlled feasibility study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type

Treatment

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Metastatic spinal cord compression

Intervention

Radiotherapy (single or multiple fractions):
Arm 1: 20 Gy/5 fractions daily for 5 consecutive days
Arm 2: 8 Gy/1 fraction

Intervention type

Other

Primary outcome measure

Patient accrual per centre over a 12-month period.

Secondary outcome measures

1. Ambulatory status at 1, 4, 8 and 12 weeks from day 1 of treatment compared to baseline
2. Bladder and bowel function at baseline compared to week 1, 4, 8 and 12
3. Acute side effects at week 1 and 4 assessed using Radiation Therapy Oncology Group (RTOG) scales
4. Quality of life at week 1, 4, 8 and 12, measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire
5. Further treatment
6. Overall survival at 3, 6 and 12 months
7. Total number of days spent in hospital
8. Preferred place of care
9. Number of patients who were eligible but not randomised and reasons for non-randomisation

Overall study start date

01/03/2008

Overall study end date

31/08/2009

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Proven diagnosis of spinal cord compression on magnetic resonance imaging (MRI)
2. Histologically or cytologically confirmed malignant disease
3. Life expectancy greater than 1 month
4. Aged 18 years or older
5. Able to give informed consent
6. Willing and able to complete assessment forms

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

100

Total final enrolment

686

Participant exclusion criteria

1. Patients for whom surgery or chemotherapy treatment is more appropriate
2. Patient known to be pregnant

Recruitment start date

01/03/2008

Recruitment end date

31/08/2009

Locations

Countries of recruitment

England, United Kingdom

Study participating centre

Mount Vernon Hospital
Northwood
HA6 2RN
United Kingdom

Sponsor information

Organisation

University College London (UCL) (UK)

Sponsor details

Medical School Administration
Gower Street
London
WC1E 6BT
England
United Kingdom

Sponsor type

University/education

Website

http://www.ucl.ac.uk/cancertrials/

ROR

https://ror.org/02jx3x895

Funders

Funder type

Charity

Funder name

Cancer Research UK (CRUK) (UK) (ref: C2422/A7932)

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 03/12/2019 04/01/2021 Yes No
Plain English results 26/10/2022 No Yes
Results article Quality-of-life outcomes 05/05/2024 07/05/2024 Yes No

Additional files

Editorial Notes

07/05/2024: Publication reference added. 25/10/2022: Cancer Research UK plain English results link added. 04/01/2021: The following changes have been made: 1. Publication reference added. 2. The total final enrolment number has been added from the reference. 26/02/2019: No publications found. All search options exhausted. 11/10/2017: No publications found, verifying study status with principal investigator. 12/05/2009: The overall trial end date was changed from 21/02/2009 to 31/08/2009. 29/04/2008: The overall trial start and end dates were updated. The initial overall trial start and end dates were: Overall trial start date: 11/11/2007 Overall trial end date: 11/11/2008